Esperion Therapeutics Inc. developing therapies that lower LDLcholesterol levels netted $165.4mm through the followon sale of 1.75mm common shares at $100 each. Funds will be used to finish developing ETC1002 for hypercholesterolemia; develop a fixeddose c...
↧